All Stories

  1. COMPLETE SUPPORT NETWORK: OFFERS, ORGANIZATION, STEERING AND COORDINATION
  2. Admission into a Nursing Home
  3. Medizin oder Jura?
  4. The state of psychogeriatrics in Europe: challenges and opportunities in six European countries
  5. Der holistische Ansatz oder die neue Ahnungslosigkeit
  6. Effects of Ginkgo biloba extract EGb 761®in dementia with neuropsychiatric features: review of recently completed randomised, controlled trials
  7. Multielectrode array analysis of cerebrospinal fluid in Alzheimer’s disease versus mild cognitive impairment: A potential diagnostic and treatment biomarker
  8. Sensitivity to change of composite and frequency scores of the Neuropsychiatric Inventory in mild to moderate dementia
  9. Gingko biloba extract EGb 761®: clinical data in dementia
  10. Ginkgo biloba extract EGb 761® in the context of current developments in the diagnosis and treatment of age-related cognitive decline and Alzheimer's disease: a research perspective
  11. Verlust an Unabhängigkeit macht Menschen im Altenheim depressiv
  12. Ein Zusammenhang ist ausgeschlossen...
  13. Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study
  14. A survey of geriatric psychiatry training across Europe
  15. Efficacy and Tolerability of a Once Daily Formulation of Ginkgo biloba Extract EGb 761® in Alzheimer's Disease and Vascular Dementia: Results from a Randomised Controlled Trial
  16. Memantine treatment reduces the intake of concomitant antipsychotics in patients with moderate Alzheimer's disease
  17. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761®. Findings from a randomized controlled trial
  18. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease
  19. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias
  20. U05-01 - Dementia
  21. Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice
  22. Normale Vergesslichkeit oder beginnende Demenz?
  23. The Relevant Outcome Scale for Alzheimer's Disease (ROSA): A new instrument for daily medical practice
  24. Verhaltensauffällig im Alter
  25. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial
  26. Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?
  27. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients
  28. Severe Impairment Battery Language scale: A language-assessment tool for Alzheimer's disease patients
  29. Welt Psychiatrie Assoziation
  30. Treatment Target Test Dementia (3TD) ©
  31. Quantitative EEG in progressingvsstable mild cognitive impairment (MCI): results of a 1-year follow-up study
  32. O3-04-03: A 240-mg once-daily formulation of Ginkgo Biloba extract EGb 761® is effective in both Alzheimer's disease and vascular dementia: Results from a randomized controlled trial
  33. Segmentation of the Spontaneous EEG in Dementia of the Alzheimer Type
  34. Odor identification in Alzheimer’s disease and depression
  35. Erkrankungen im Alter
  36. Der TFDD
  37. EEG and the Test for the Early Detection of Dementia with Discrimination from Depression(TE4D): a validation study
  38. Ärztliche Weiterbildung in der Gerontopsychiatrie - eine fähigkeitsorientierte Leitlinie
  39. Physiologische Altersveränderungen bei EEG-Segmentation?
  40. Psychometric tests and glucose metabolism
  41. Electrophysiological correlates of emotional and structural face processing in humans
  42. Differential Diagnosis of Aging, Dementia of the Alzheimer Type and Depression with EEG-Segmentation
  43. Klinische Diagnosekriterien
  44. Anwendung von Neuroleptika in der Gerontopsychiatrie
  45. Zur Nootropikabewertung für die Praxis
  46. Alzheimers Disease Assessment Scale: Reliability and Validity in a Multicenter Clinical Trial
  47. Vorbemerkungen
  48. Topography of the maximum of the amplitude of EEG frequency bands in dementia of the Alzheimer type
  49. Demenz und Schilddrüsenstörungen
  50. Event-Related Potentials and Psychopharmacology
  51. Age-related changes of spontaneous EEG described by equivalent dipoles
  52. Dementia of the alzheimer type: Effects on the spontaneous EEG described by dipole sources
  53. Hilfestellungen für Angehörige und Pflegende
  54. Rechtliche Probleme
  55. Begriffsbestimmung des dementieilen Syndroms
  56. Therapeutische Ansätze und Prophylaxe
  57. Epidemiologie
  58. Diagnostik
  59. Aloys Alzheimer (14.6. 1864 -19.12. 1915)
  60. Biologische Grundlagen der Demenz vom Alzheimer-Typ
  61. Hypothesen zur Ätiologie der Demenz vom Alzheimer-Typ
  62. Risikofaktoren der Demenz vom Alzheimer-Typ
  63. Strukturelle und funktionelle Bildgebung in der Gerontopsychiatrie
  64. Versorgungsstruktur für Patienten mit Demenzerkrankungen und deren Angehörige in einer Region (Unterfranken)
  65. Neue therapeutische Strategien bei der Behandlung von Demenzen
  66. Alzheimer
  67. Differential validity of psychometric tests in dementia of the Alzheimer type
  68. Klinische Bewertung der Wirksamkeit von Nootropika
  69. Glukose- und Sauerstoffmetabolismus bei Demenz vom Alzheimer-Typ
  70. EFFECTS OF NEUROTRANSMITTERACTIVATION ON COMPUTERIZED EEG-TOPOGRAPHY (CET)
  71. Topographical QEEG-alterations in dementia of Alzheimer type
  72. Topography of the quantitative electroencephalogram in dementia of the alzheimer type: Relation to severity of dementia
  73. The effect of pyritinol upon P300 topography
  74. Influence of Physostigmine on Cognitive Processing of the Brain
  75. Effects of Pyritinol on the Distribution of Electrical Brain Activity
  76. Topographie der P300 in der Psychiatrie - II. Kognitive P300-Felder bei Demenz
  77. Demenzen